Evaluation of therapeutic effect of baricitinib in patients with severe pneumonia requiring non-invasive ventilation induced to Covid 19

Phase 3

Recruiting

Conditions: Acute viral infection caused by the corona virus (COVID-19).
COVID-19, virus identified
U07.1

Registration Number: IRCT20220508054780N1

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 15

Inclusion Criteria

Patients with severe covid 19 who fullfill PCR or radiological criteria for covid 19 clinical symptoms
History of respiratory symptoms from one week before, with a diagnosis of acute respiratory failure
Requires non-invasive ventilation to maintain O2 saturation above 85% in IC

Exclusion Criteria

Increased liver enzymes and renal failure
Bacterial, fungal and viral infections
Bone marrow suppression and decrease in leukocytes

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The mortality rate of patients with acute respiratory infection of the coronavirus who admitted in ICU. Timepoint: 30, 60 and 90 days. Method of measurement: observation of the number of dead patients.;Score of disease severity questionnaire (APACHEII). Timepoint: 30, 60 and 90 days. Method of measurement: APACHEII questionnaire.;Number of days that a patient is on ventilator. Timepoint: 30, 60 and 90 days. Method of measurement: observation of the number of days the patient is on ventilator.;Incidence of sepsis. Timepoint: 30, 60 and 90 days. Method of measurement: Evaluation of the patient's clinical symptoms and laboratory findings.;Incidence of respiratory distress. Timepoint: 30, 60 and 90 days. Method of measurement: Clinical evaluation of respiratory distress in patients.

Secondary Outcome Measures